Literature DB >> 28362938

The Use of Noncarbapenem β-Lactams for the Treatment of Extended-Spectrum β-Lactamase Infections.

Pranita D Tamma1, Jesus Rodriguez-Bano2.   

Abstract

The continued rise in infections caused by extended-spectrum β-lactamase (ESBL)-producing pathogens is recognized globally as one of the most pressing concerns facing the healthcare community. Carbapenems are widely regarded as the antibiotics of choice for the treatment of ESBL-producing infections, even when in vitro activity to other β-lactams has been demonstrated. However, indiscriminant carbapenem use is not without consequence, and carbapenem overuse has contributed to the emergence of carbapenem-resistant Enterobacteriaceae. The use of non-carbapenem β-lactams for the treatment of ESBL infections has yielded conflicting results. In this review, we discuss the available data for the use of cephamycins, cefepime, piperacillin-tazobactam, ceftolozane-tazobactam, and ceftazidime-avibactam for the treatment of ESBL infections.
© The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  ESBLs; carbapenems; cefepime; cephamycins; piperacillin-tazobactam.

Mesh：

Substances：

Year:  2017        PMID： 28362938      PMCID： PMC5848369          DOI： 10.1093/cid/cix034

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  60 in total

1.  Endocarditis caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: emergence of resistance to ciprofloxacin and piperacillin-tazobactam during treatment despite initial susceptibility.

Authors:  Oren Zimhony; Inna Chmelnitsky; Rita Bardenstein; Sorel Goland; Orly Hammer Muntz; Shiri Navon Venezia; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

2.  Efficacy of different beta-lactams against an extended-spectrum beta-lactamase-producing Klebsiella pneumoniae strain in the rat intra-abdominal abscess model.

Authors:  L B Rice; J D Yao; K Klimm; G M Eliopoulos; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

3.  Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012).

Authors:  Helio S Sader; David J Farrell; Robert K Flamm; Ronald N Jones
Journal:  J Infect       Date:  2014-04-26       Impact factor: 6.072

4.  Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum beta-lactamase-producing Enterobacteriaceae: MIC matters.

Authors:  Nan-Yao Lee; Ching-Chi Lee; Wei-Han Huang; Ko-Chung Tsui; Po-Ren Hsueh; Wen-Chien Ko
Journal:  Clin Infect Dis       Date:  2012-10-22       Impact factor: 9.079

5.  Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates.

Authors:  L López-Cerero; E Picón; C Morillo; J R Hernández; F Docobo; J Pachón; J Rodríguez-Baño; A Pascual
Journal:  Clin Microbiol Infect       Date:  2009-07-15       Impact factor: 8.067

6.  Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study.

Authors:  G Zanetti; F Bally; G Greub; J Garbino; T Kinge; D Lew; J-A Romand; J Bille; D Aymon; L Stratchounski; L Krawczyk; E Rubinstein; M-D Schaller; R Chiolero; M-P Glauser; A Cometta
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

7.  Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases.

Authors:  David L Paterson; Wen-Chien Ko; Anne Von Gottberg; Sunita Mohapatra; Jose Maria Casellas; Herman Goossens; Lutfiye Mulazimoglu; Gordon Trenholme; Keith P Klugman; Robert A Bonomo; Louis B Rice; Marilyn M Wagener; Joseph G McCormack; Victor L Yu
Journal:  Clin Infect Dis       Date:  2004-06-08       Impact factor: 9.079

Review 8.  Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins.

Authors:  W A Craig
Journal:  Diagn Microbiol Infect Dis       Date:  1995 May-Jun       Impact factor: 2.803

9.  Determination of the in vivo pharmacodynamic profile of cefepime against extended-spectrum-beta-lactamase-producing Escherichia coli at various inocula.

Authors:  Dana Maglio; Christine Ong; Mary Anne Banevicius; Qiuming Geng; Charles H Nightingale; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

10.  In vitro activities of various beta-lactam antimicrobial agents against clinical isolates of Escherichia coli and Klebsiella spp. resistant to oxyimino cephalosporins.

Authors:  B D Jett; D J Ritchie; R Reichley; T C Bailey; D F Sahm
Journal:  Antimicrob Agents Chemother       Date:  1995-05       Impact factor: 5.191
View more
  49 in total

1.  Carbapenem versus Cefepime or Piperacillin-Tazobactam for Empiric Treatment of Bacteremia Due to Extended-Spectrum-β-Lactamase-Producing Escherichia coli in Patients with Hematologic Malignancy.

Authors:  Grace E Benanti; Anne Rain T Brown; Terri Lynn Shigle; Jeffrey J Tarrand; Micah M Bhatti; Patrick M McDaneld; Samuel A Shelburne; Samuel L Aitken
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

2.  Piperacillin-Tazobactam Versus Carbapenems for the Treatment of Nonbacteremic Urinary Tract Infections due to Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae.

Authors:  Jordan Brooke Tullos; Laura Leigh Stoudenmire; Jonathon David Pouliot
Journal:  Hosp Pharm       Date:  2018-12-07

3.  The Inoculum Effect in the Era of Multidrug Resistance: Minor Differences in Inoculum Have Dramatic Effect on MIC Determination.

Authors:  Kenneth P Smith; James E Kirby
Journal:  Antimicrob Agents Chemother       Date:  2018-07-27       Impact factor: 5.191

4.  Is Piperacillin-Tazobactam Effective for the Treatment of Pyelonephritis Caused by Extended-Spectrum β-Lactamase-Producing Organisms?

Authors:  Sima L Sharara; Joe Amoah; Zoi D Pana; Patricia J Simner; Sara E Cosgrove; Pranita D Tamma
Journal:  Clin Infect Dis       Date:  2020-11-05       Impact factor: 9.079

5.  In Vivo Activity of WCK 4282 (High-Dose Cefepime/Tazobactam) against Serine-β-Lactamase-Producing Enterobacterales and Pseudomonas aeruginosa in the Neutropenic Murine Lung Infection Model.

Authors:  Maxwell J Lasko; Kamilia Abdelraouf; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2021-03-18       Impact factor: 5.191

6.  Pharmacokinetics-Pharmacodynamics of Enmetazobactam Combined with Cefepime in a Neutropenic Murine Thigh Infection Model.

Authors:  Fabian Bernhard; Rajesh Odedra; Sylvie Sordello; Rossella Cardin; Samantha Franzoni; Cédric Charrier; Adam Belley; Peter Warn; Matthias Machacek; Philipp Knechtle
Journal:  Antimicrob Agents Chemother       Date:  2020-05-21       Impact factor: 5.191

7.  Development of Broth Microdilution MIC and Disk Diffusion Antimicrobial Susceptibility Test Quality Control Ranges for the Combination of Cefepime and the Novel β-Lactamase Inhibitor Enmetazobactam.

Authors:  Adam Belley; Michael D Huband; Kelley A Fedler; Amy A Watters; Robert K Flamm; Stuart Shapiro; Philipp Knechtle
Journal:  J Clin Microbiol       Date:  2019-07-26       Impact factor: 5.948

8.  Efficacy of cefoxitin versus carbapenem in febrile male urinary tract infections caused by extended spectrum beta-lactamase-producing Escherichia coli: a multicenter retrospective cohort study with propensity score analysis.

Authors:  O Senard; M Lafaurie; P Lesprit; Y Nguyen; X Lescure; A Therby; V Fihman; N Oubaya; R Lepeule
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-09-11       Impact factor: 3.267

9.  Multicenter Evaluation of the New Etest Gradient Diffusion Method for Piperacillin-Tazobactam Susceptibility Testing of Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii Complex.

Authors:  Sergio García-Fernández; Yohann Bala; Tom Armstrong; María García-Castillo; C A Burnham; Meghan A Wallace; Dwight Hardy; Gilles Zambardi; Rafael Cantón
Journal:  J Clin Microbiol       Date:  2020-01-28       Impact factor: 5.948

10.  The impact of nephrostomy drainage prior to mini-percutaneous nephrolithotomy in patients with ESBL-positive Escherichia coli.

Authors:  Zhijian Zhao; Wenqi Wu; Tao Zeng; Xiangkun Wu; Yongda Liu; Guohua Zeng
Journal:  World J Urol       Date:  2020-03-20       Impact factor: 4.226
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.